IP Library › Granted Patent US 12691144
Granted Patent B2
US 12691144 · App. 18/546,979 · Granted Jul 28, 2026

Ovotransferrins for use in the treatment of iron deficiency anaemia

Inventors: Valerio Maria Ferrari (Milan, IT); Maria Carla Baggio (Saronno, IT); Paride Grisenti (Milan, IT)
Assignee: BIOSEUTICA B.V.
A61K38/40A61K33/26A61P3/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691144
App. No.
18/546,979
Granted
Jul 28, 2026
Kind
B2
Abstract

Ovotransferrins with a degree of iron saturation from 0 to 15% are useful in the treatment of iron deficiency and iron deficiency anaemia, increasing the cell viability on gastric and intestinal cell models with respect to the holo-OvT 100%, when tested at the same concentrations, showing also a surprisingly better time dependent absorption of iron ions and a physiological trend allowing a single oral administration in 24 hours.

Claims (6)

1 . A method of treating iron deficiency and iron deficiency anaemia in a subject in need thereof, said method comprising

administering to said subject a pharmaceutical effective amount of ovotransferrin with an iron content from 1 ppm to 246 ppm.

2 . The method according to claim 1 , wherein said ovotransferrin has an iron content from 1 to 10 ppm.

3 . The method according to claim 1 , wherein said ovotransferrin has an iron content from 20 ppm to 246 ppm.

4 . The method according to claim 3 , wherein said ovotransferrin has an iron content of 221-227 ppm.

5 . The method according to claim 1 wherein ovotransferrin is administered at a daily dose ranging from 100 to 400 mg in a single dose or twice a day.